WONCA研究论文摘要汇编——德国全科医疗抗凝治疗的整群随机对照试验筛查
[Abstract]:Objective to treat the complications of thrombus embolism with oral anticoagulant (OAC) combined with coumarin. However, studies have shown that anticoagulant is often overused or insufficient in treatment. In this paper, the correct treatment of patients taking OAC for a long time was discussed, and the related characteristics of these patients were summarized according to the screening results of cluster random PICANT test. Methods the general clinic was randomly selected in Hesse, Germany, and the research members were visited. Use the general practitioner software to generate a list of anonymous patients with predetermined instructions, and use the anonymous list to investigate eligible patients. The eligible patients were divided into three groups: group A (patients with long-term use of OAC indication and taking anticoagulant), group B (patients with long-term use of OAC indication but not anticoagulant) and group C (patients who did not have long-term OAC indication but took anticoagulant for a long time). Descriptive statistical analysis was carried out with SPSS 20.0 software. Results 2036 eligible patients were included in 52 general practice clinics, of which 275 patients were excluded because they could not be classified. Finally, 1761 cases were included in the study, including 1641 cases in group A, 78 cases in group B and 42 cases in group C. The international standardized ratio (INR),) of 1 504 patients was obtained. The INR of 1 013 patients was in the treatment range. General practitioners software evaluation found that most patients had good treatment compliance, 6.1% of patients took new anticoagulant. Conclusion the anticoagulant therapy of most patients is correct. The patients who should use OAC for a long time but not take anticoagulant for a long time and those who should not use OAC for a long time but take anticoagulant for a long time are lower than expected. The control effect of OAC is within a reasonable and high range.
【分类号】:R96
【相似文献】
相关期刊论文 前10条
1 王亚军,,李烨;日产化学工业和绿十字公司的新型口服血小板抗凝剂[J];药学进展;1994年04期
2 Walker ID,Machin S,Baglin TP,吴淑燕,王兆钺;口服抗凝剂指南(第三版)[J];国外医学.输血及血液学分册;2004年06期
3 徐革;刘洪学;;抗凝剂对酶活性的影响[J];四川省卫生管理干部学院学报;2007年03期
4 王拥军;;卷首语[J];中国新药杂志;2012年11期
5 韩秀霞;;口服抗凝剂[J];国外医学情报;1998年05期
6 王晓东;刘兴会;;抗凝剂的种类及其在妊娠中的应用[J];中国实用妇科与产科杂志;2006年03期
7 藤井彰;李森;;阿斯匹林作抗凝剂使用时应小剂量缓慢给药[J];黑龙江医药科学;1987年03期
8 李蓉;乔杰;;抗凝剂在生殖领域中的应用[J];中国实用妇科与产科杂志;2006年03期
9 张心声;血浆和枸椽酸钠抗凝剂中铝的含量[J];国外医学.输血及血液学分册;1992年05期
10 吴立志,陈槐卿,邓力;抗凝剂、温度和性别对体外中性粒细胞自发性激活的影响[J];生物医学工程学杂志;1999年03期
相关会议论文 前1条
1 陈颖;侯建明;陈国龙;林豪;林洪铿;褚晓凌;曾嘉;陈岑;林娟;Markus Dettke;;钙剂补充减轻柠檬酸盐抗凝剂对献血者骨代谢的影响[A];中国输血协会第五届输血大会论文专集(摘要篇)[C];2010年
相关重要报纸文章 前1条
1 国讯;多个国家警示新型口服抗凝剂的出血风险[N];中国医药报;2013年
本文编号:2502204
本文链接:https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2502204.html